Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

CD73 + CD127 high Long-Term Memory CD4 T Cells Are Highly Proliferative in Response to Recall Antigens and Are Early Targets in HIV-1 Infection.

Tytuł:
CD73 Long-Term Memory CD4 T Cells Are Highly Proliferative in Response to Recall Antigens and Are Early Targets in HIV-1 Infection.
Autorzy:
Seddiki N; INSERM U955, Equipe 16, 94000 Créteil, France.; Faculté de médecine, Université Paris-Est Créteil, 94000 Créteil, France.; Vaccine Research Institute (VRI), 94000 Créteil, France.
Zaunders J; Centre for Applied Medical Research, St Vincent's Hospital, Sydney, NSW 2010, Australia.; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Phetsouphanh C; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Brezar V; INSERM U955, Equipe 16, 94000 Créteil, France.
Xu Y; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
McGuire HM; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.; Ramaciotti Facility for Human Systems Biology, The University of Sydney, Sydney, NSW 2006, Australia.; Discipline of Pathology, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
Bailey M; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
McBride K; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Hey-Cunningham W; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Munier CML; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Cook L; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Kent S; Department of Microbiology and Immunology, University of Melbourne, Melbourne, VIC 3010, Australia.
Lloyd A; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Cameron B; School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
Fazekas de St Groth B; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.; Ramaciotti Facility for Human Systems Biology, The University of Sydney, Sydney, NSW 2006, Australia.; Discipline of Pathology, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
Koelsch K; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Danta M; St Vincent's Clinical School, St Vincent's Hospital and University of New South Wales, Sydney, NSW 2052, Australia.
Hocini H; INSERM U955, Equipe 16, 94000 Créteil, France.
Levy Y; INSERM U955, Equipe 16, 94000 Créteil, France.; Faculté de médecine, Université Paris-Est Créteil, 94000 Créteil, France.; Vaccine Research Institute (VRI), 94000 Créteil, France.; AP-HP, Hôpital H. Mondor-A. Chenevier, Service d'immunologie Clinique et Maladies Infectieuses, 94000 Créteil, France.
Kelleher AD; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Jan 18; Vol. 22 (2). Date of Electronic Publication: 2021 Jan 18.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Molecular Targeted Therapy*
Antigens, CD/*immunology
Cell Proliferation/*genetics
HIV Infections/*genetics
5'-Nucleotidase/genetics ; 5'-Nucleotidase/immunology ; Antigens, CD/genetics ; Antigens, CD/therapeutic use ; Cell Lineage/genetics ; Cell Lineage/immunology ; HIV Infections/immunology ; HIV Infections/pathology ; HIV Infections/virology ; HIV-1/immunology ; HIV-1/pathogenicity ; Humans ; Interleukin-7 Receptor alpha Subunit/genetics ; Interleukin-7 Receptor alpha Subunit/immunology ; Memory, Long-Term/physiology
References:
AIDS. 2000 Jun 16;14(9):1171-80. (PMID: 10894281)
Arterioscler Thromb Vasc Biol. 2019 Mar;39(3):339-348. (PMID: 30676071)
AIDS. 2011 Nov 13;25(17):2069-78. (PMID: 21860347)
Annu Rev Immunol. 2004;22:745-63. (PMID: 15032595)
J Infect Dis. 1985 Mar;151(3):459-63. (PMID: 2982964)
Eur J Immunol. 1998 Oct;28(10):2981-90. (PMID: 9808167)
AIDS Res Hum Retroviruses. 2019 Jan;35(1):112-120. (PMID: 30511878)
Immunol Rev. 1998 Feb;161:95-109. (PMID: 9553767)
Clin Infect Dis. 2012 Jul;55(2):291-300. (PMID: 22550117)
Clin Cancer Res. 2009 Oct 15;15(20):6348-57. (PMID: 19825957)
Blood. 2007 Aug 15;110(4):1225-32. (PMID: 17449799)
Front Immunol. 2016 Oct 24;7:438. (PMID: 27822211)
J Exp Med. 2007 Jun 11;204(6):1257-65. (PMID: 17502665)
J Immunol Methods. 2012 Jan 31;375(1-2):148-58. (PMID: 22019644)
Blood. 2004 Mar 15;103(6):2238-47. (PMID: 14645006)
J Immunol. 1996 Feb 15;156(4):1349-55. (PMID: 8568233)
Purinergic Signal. 2012 Sep;8(3):437-502. (PMID: 22555564)
J Virol. 2006 Oct;80(20):10151-61. (PMID: 17005692)
N Engl J Med. 2000 Oct 5;343(14):1020-34. (PMID: 11018170)
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):542-6. (PMID: 8421688)
Vaccine. 2009 Jun 2;27(27):3576-83. (PMID: 19464537)
J Exp Med. 2006 Jul 10;203(7):1693-700. (PMID: 16818676)
Blood. 2011 Apr 21;117(16):4387-93. (PMID: 21346249)
AIDS Res Hum Retroviruses. 2017 Jul;33(7):648-657. (PMID: 28287825)
J Immunol. 2002 Jun 1;168(11):5954-8. (PMID: 12023402)
Trends Immunol. 2011 Sep;32(9):428-33. (PMID: 21723783)
J Infect Dis. 2006 Mar 1;193(5):664-71. (PMID: 16453261)
PLoS One. 2013 Oct 04;8(10):e74946. (PMID: 24124462)
J Clin Invest. 1995 Jun;95(6):2945-53. (PMID: 7769137)
J Leukoc Biol. 2013 Oct;94(4):545-7. (PMID: 24082048)
J Immunol. 2009 Aug 15;183(4):2827-36. (PMID: 19635903)
J Immunol. 2009 Dec 1;183(11):7602-10. (PMID: 19917691)
J Infect Dis. 1999 Aug;180(2):320-9. (PMID: 10395845)
Eur J Immunol. 2014 Jun;44(6):1644-61. (PMID: 24752698)
J Exp Med. 2004 Sep 20;200(6):749-59. (PMID: 15365096)
J Virol. 2011 Feb;85(3):1287-97. (PMID: 21047964)
Bioinformatics. 2003 Oct 12;19(15):1945-51. (PMID: 14555628)
Clin Exp Immunol. 2014 Aug;177(2):531-43. (PMID: 24749746)
J Leukoc Biol. 2017 May;101(5):1263-1271. (PMID: 28193736)
J Virol. 2004 Apr;78(8):3811-6. (PMID: 15047796)
AIDS. 2020 May 1;34(6):833-848. (PMID: 32044843)
J Leukoc Biol. 2013 Oct;94(4):551-61. (PMID: 23709688)
Eur J Immunol. 2009 Feb;39(2):391-403. (PMID: 19180462)
Immunity. 2019 Dec 17;51(6):970-972. (PMID: 31851902)
J Virol. 2006 Oct;80(20):10162-72. (PMID: 17005693)
J Exp Med. 2004 Dec 6;200(11):1395-405. (PMID: 15583013)
J Immunol. 2008 May 1;180(9):6288-96. (PMID: 18424752)
Front Immunol. 2018 Jul 26;9:1672. (PMID: 30093901)
Eur J Immunol. 2012 Nov;42(11):3062-72. (PMID: 22965858)
Blood. 2005 Sep 1;106(5):1660-7. (PMID: 15905189)
Front Immunol. 2013 Apr 24;4:95. (PMID: 23630526)
Am J Transplant. 2010 Nov;10(11):2410-20. (PMID: 20977632)
AIDS. 2012 Mar 13;26(5):543-50. (PMID: 22410637)
AIDS. 2013 Jun 19;27(10):1545-55. (PMID: 24005375)
AIDS Res Hum Retroviruses. 2013 Oct;29(10):1330-9. (PMID: 23971972)
J Infect Dis. 1996 Feb;173(2):321-9. (PMID: 8568292)
Cell Rep. 2016 Nov 8;17(7):1773-1782. (PMID: 27829149)
J Allergy Clin Immunol. 2017 Dec;140(6):1592-1603.e8. (PMID: 28283419)
Immunology. 1997 Oct;92(2):173-9. (PMID: 9415023)
Exp Cell Res. 2004 Jun 10;296(2):99-108. (PMID: 15149841)
AIDS. 1995 Jun;9(6):561-6. (PMID: 7662193)
Front Immunol. 2019 Nov 08;10:2521. (PMID: 31781093)
J Immunol. 2011 Aug 15;187(4):1542-6. (PMID: 21724993)
Cytokine Growth Factor Rev. 2014 Aug;25(4):391-401. (PMID: 25130296)
J Virol. 2003 Oct;77(20):10900-9. (PMID: 14512540)
Clin Exp Immunol. 2020 May;200(2):108-119. (PMID: 31828774)
Vaccine. 2016 Oct 17;34(44):5251-5261. (PMID: 27639281)
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9325-30. (PMID: 18591671)
J Virol. 2014 Mar;88(6):3516-26. (PMID: 24403590)
Grant Information:
1063422 National Health and Medical Research Council; 1052979 National Health and Medical Research Council; 1037298 National Health and Medical Research Council
Contributed Indexing:
Keywords: CD4+ subsets; CD73; HIV-1 viral reservoir
Substance Nomenclature:
0 (Antigens, CD)
0 (Interleukin-7 Receptor alpha Subunit)
EC 3.1.3.5 (5'-Nucleotidase)
Entry Date(s):
Date Created: 20210122 Date Completed: 20210907 Latest Revision: 20210907
Update Code:
20240105
PubMed Central ID:
PMC7831934
DOI:
10.3390/ijms22020912
PMID:
33477692
Czasopismo naukowe
HIV-1 infection rapidly leads to a loss of the proliferative response of memory CD4+ T lymphocytes, when cultured with recall antigens. We report here that CD73 expression defines a subset of resting memory CD4+ T cells in peripheral blood, which highly express the α-chain of the IL-7 receptor (CD127), but not CD38 or Ki-67, yet are highly proliferative in response to mitogen and recall antigens, and to IL-7, in vitro. These cells also preferentially express CCR5 and produce IL-2. We reasoned that CD73+ memory CD4+ T cells decrease very early in HIV-1 infection. Indeed, CD73+ memory CD4+ T cells comprised a median of 7.5% (interquartile range: 4.5-10.4%) of CD4+ T cells in peripheral blood from healthy adults, but were decreased in primary HIV-1 infection to a median of 3.7% (IQR: 2.6-6.4%; p = 0.002); and in chronic HIV-1 infection to 1.9% (IQR: 1.1-3%; p < 0.0001), and were not restored by antiretroviral therapy. Moreover, we found that a significant proportion of CD73+ memory CD4+ T cells were skewed to a gut-homing phenotype, expressing integrins α4 and β7, CXCR3, CCR6, CD161 and CD26. Accordingly, 20% of CD4+ T cells present in gut biopsies were CD73+. In HIV+ subjects, purified CD73+ resting memory CD4+ T cells in PBMC were infected with HIV-1 DNA, determined by real-time PCR, to the same level as for purified CD73-negative CD4+ T cells, both in untreated and treated subjects. Therefore, the proliferative CD73+ subset of memory CD4+ T cells is disproportionately reduced in HIV-1 infection, but, unexpectedly, their IL-7 dependent long-term resting phenotype suggests that residual infected cells in this subset may contribute significantly to the very long-lived HIV proviral DNA reservoir in treated subjects.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies